A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris?

References

• Bystryn JC, Rudolph JL. Pemphigus. Lancet366(9479), 61–73 (2005).
   PubMed Web of Science ®Google Scholar
• Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest.116(5), 1159–1166 (2006).
   PubMed Web of Science ®Google Scholar
• Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J. Invest. Dermatol.67(2), 254–260 (1976).
   PubMed Web of Science ®Google Scholar
• Schiltz JR, Michel B, Papay R. Pemphigus antibody interaction with human epidermal cells in culture. J. Clin. Invest.62(4), 778–788 (1978).
   PubMed Web of Science ®Google Scholar
• Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest.105(5), 625–631 (2000).
   PubMed Web of Science ®Google Scholar
• Shimizu A, Ishiko A, Ota T et al.Ultrastructural changes in mice actively producing antibodies to desmoglein 3 parallel those in patients with pemphigus vulgaris. Arch. Dermatol. Res.294(7), 318–323 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. J. Invest. Dermatol.122(5), 1145–1153 (2004).
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Hu P, Liu Z et al. Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J. Biol. Chem.280(25), 23778–23784 (2005).
   PubMed Web of Science ®Google Scholar
• Sánchez-Carpintero I, España A, Pelacho B et al.In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br. J. Dermatol.151(3), 565–570 (2004).
   PubMed Web of Science ®Google Scholar
• Puviani M, Marconi A, Cozzani E, Pincelli C. Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. J. Invest. Dermatol.120(1), 164–167 (2003).
   PubMed Web of Science ®Google Scholar
• Wang X, Brégégère F, Frusić-Zlotkin M, Feinmesser M, Michel B, Milner Y. Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins. Apoptosis9(2), 131–143 (2004).
   PubMed Web of Science ®Google Scholar
• Grando SA, Bystryn JC, Chernyavsky AI et al. Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp. Dermatol.18(9), 764–770 (2009).
   PubMed Web of Science ®Google Scholar
• España A, Diaz LA, Mascaró JM Jr et al. Mechanisms of acantholysis in pemphigus foliaceus. Clin. Immunol. Immunopathol.85(1), 83–89 (1997).
   PubMedGoogle Scholar
• Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J. Invest. Dermatol.113(1), 22–25 (1999).
   PubMed Web of Science ®Google Scholar
• Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1α and TNF-α in in vitro acantholysis. Exp. Dermatol.12(4), 466–471 (2003).
   PubMed Web of Science ®Google Scholar
• Feliciani C, Toto P, Amerio P et al.In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J. Invest. Dermatol.114(1), 71–77 (2000).
   PubMed Web of Science ®Google Scholar
• Amagai M, Ahmed AR, Kitajima Y et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease’? Exp. Dermatol.15(10), 815–831 (2006).
   PubMed Web of Science ®Google Scholar
• Vu TN, Lee TX, Ndoye A et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. Arch. Dermatol.134(8), 971–980 (1998).
   PubMedGoogle Scholar
• El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J. Am. Acad. Dermatol.55(3), 449–459 (2006).
   PubMed Web of Science ®Google Scholar
• Dupuy A, Viguier M, Bédane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol.140(1), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol.153(3), 620–625 (2005).
   PubMed Web of Science ®Google Scholar
• Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol.47(5), 785–788 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin. Exp. Dermatol.28(4), 366–368 (2003).
   PubMed Web of Science ®Google Scholar
• Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit. Rev. Oral Biol. Med.13(5), 397–408 (2002).
   PubMedGoogle Scholar
• Ruocco V, Pisani M, de Angelis E, Lombardi ML. Biochemical acantholysis provoked by thiol drugs. Arch. Dermatol.126(7), 965–966 (1990).
   PubMedGoogle Scholar
• Brenner S, Tur E, Shapiro J et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int. J. Dermatol.40(9), 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Serrano J, Puupponen-Pimiä R, Dauer A, Aura AM, Saura-Calixto F. Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol. Nutr. Food Res.53(Suppl. 2), S310–S329 (2009).
   PubMed Web of Science ®Google Scholar
• Rasmussen SE, Frederiksen H, Struntze Krogholm K, Poulsen L. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol. Nutr. Food Res.49(2), 159–174 (2005).
   PubMed Web of Science ®Google Scholar
• Ruocco V, Brenner S, Ruocco E. Pemphigus and diet: does a link exist? Int. J. Dermatol.40(3), 161–163 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner S, Ruocco V, Ruocco E et al. In vitro tannin acantholysis. Int. J. Dermatol.39(10), 738–742 (2000).
   PubMed Web of Science ®Google Scholar
• Feliciani C, Ruocco E, Zampetti A et al. Tannic acid induces in vitro acantholysis of keratinocytes via IL-1α and TNF-α. Int. J. Immunopathol. Pharmacol.20(2), 289–299 (2007).
   PubMed Web of Science ®Google Scholar